Skip to content
Sign in
StableHealthReported 2026-11-14 11:48

Innovent announces seven products included in 2026 National Reimbursement Drug List

Innovent Biologics announced that seven innovative products, including mazdutide and PECONDLE®, were successfully included in the updated 2026 National Reimbursement Drug List (NRDL), with the updated list taking effect from January 1, 2027. Products newly added to the NRDL include mazdutide (a GCG/GLP-1 dual receptor agonist) for type 2 diabetes, PECONDLE® (picankibart injection) for unspecified indications, TABOSUN®, and Vanflyta®. Products with new indications include TYVYT®, Jaypirca®, and SINTBILO® renewal.

Why it matters. The inclusion of these innovative drugs in the NRDL expands patient access and affordability in China, potentially benefiting over 20 million patients cumulatively and reinforcing Innovent's position in oncology, metabolic, and autoimmune…

01

Who and what it touches

Lillycompetes withPfizerpartners withAltruist Biologicsownsinnovative drugsmanufacturesTakeda Pharmaceuticalagreement withOllininvests inOLN324suppliesEli Lillypartners withInnovent

Into Innovent

From Innovent

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-14 11:48
    Picankibart is the first and only domestic IL-23p19 inhibitor
    View source